Skip to main content
. 2024 Feb 6;15:1094. doi: 10.1038/s41467-024-45449-y

Fig. 3. Clonotypic response of γδ T cells in a MCC patient upon pembrolizumab treatment.

Fig. 3

γδ T cells were sorted from the peripheral blood at baseline and week 6 after pembrolizumab treatment and TCRγ chains were sequenced. A Diversity 50 (D50) index on TRG CDR3 clonotypes from five MCC patients are shown. D50 index is the minimum number of unique clonotypes to occupy 50% of the total repertoire. B Changes in the frequency of top 10 clonotypes by CDR3 a.a. sequence for the complete responder patient E-013 (left) and progressive disease patient E-035 (right). The TCRγ CDR3 sequence CATWDGSRSYYKKLF is shown for the top expanded clonotype from patient E-013. C Frequency of top 10 clonotypes for the partial responders E-020 (left), E-022 (middle), and progressive disease patient E-034 (right). D Comparison of the top 10 TCRδ CDR3 sequences of γδ T cells sorted from week 6 blood with TCRδ sequenced from an FFPE tumor sample taken when a new lesion arose in patient E-013 after pembrolizumab treatment was stopped due to intercurrent illness. The TCRδ CDR3 sequence CALGDYVLSDKLIF is shown for the most abundant clonotype.